Equities analysts expect that Five Prime Therapeutics Inc (NASDAQ:FPRX) will report $4.33 million in sales for the current quarter, Zacks reports. Five analysts have issued estimates for Five Prime Therapeutics’ earnings, with estimates ranging from $2.83 million to $5.80 million. Five Prime Therapeutics posted sales of $5.77 million during the same quarter last year, which suggests a negative year over year growth rate of 25%. The business is scheduled to issue its next earnings results after the market closes on Tuesday, November 5th.
According to Zacks, analysts expect that Five Prime Therapeutics will report full-year sales of $17.37 million for the current fiscal year, with estimates ranging from $8.70 million to $26.00 million. For the next financial year, analysts expect that the firm will report sales of $51.25 million, with estimates ranging from $20.00 million to $139.00 million. Zacks’ sales averages are an average based on a survey of analysts that follow Five Prime Therapeutics.
Five Prime Therapeutics (NASDAQ:FPRX) last posted its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.09). The business had revenue of $3.33 million for the quarter, compared to analysts’ expectations of $5.53 million. Five Prime Therapeutics had a negative return on equity of 62.13% and a negative net margin of 842.84%.
Several research analysts recently commented on the stock. Zacks Investment Research raised shares of Five Prime Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 6th. ValuEngine raised shares of Five Prime Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, Guggenheim downgraded shares of Five Prime Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, September 30th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $14.40.
Shares of NASDAQ FPRX traded up $0.20 during mid-day trading on Wednesday, hitting $4.04. The stock had a trading volume of 630,800 shares, compared to its average volume of 369,827. The company has a debt-to-equity ratio of 0.23, a quick ratio of 6.87 and a current ratio of 6.87. Five Prime Therapeutics has a 1 year low of $3.22 and a 1 year high of $13.97. The business has a 50 day moving average price of $4.50 and a two-hundred day moving average price of $6.73. The firm has a market cap of $137.56 million, a P/E ratio of -0.98 and a beta of 2.57.
In other Five Prime Therapeutics news, insider Value Fund L. P. Biotechnology bought 169,370 shares of the company’s stock in a transaction dated Friday, October 25th. The shares were purchased at an average price of $4.10 per share, for a total transaction of $694,417.00. Also, insider Value Fund L. P. Biotechnology bought 601,482 shares of the company’s stock in a transaction dated Tuesday, October 8th. The shares were acquired at an average price of $3.74 per share, for a total transaction of $2,249,542.68. In the last quarter, insiders purchased 1,345,904 shares of company stock worth $5,100,245. 7.10% of the stock is currently owned by company insiders.
Several hedge funds have recently made changes to their positions in the company. BlackRock Inc. boosted its holdings in shares of Five Prime Therapeutics by 2.3% during the 2nd quarter. BlackRock Inc. now owns 2,882,588 shares of the biotechnology company’s stock valued at $17,382,000 after buying an additional 63,634 shares in the last quarter. Man Group plc boosted its holdings in shares of Five Prime Therapeutics by 95.9% during the 2nd quarter. Man Group plc now owns 1,160,411 shares of the biotechnology company’s stock valued at $6,997,000 after buying an additional 568,017 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Five Prime Therapeutics by 86.5% during the 2nd quarter. Renaissance Technologies LLC now owns 1,149,200 shares of the biotechnology company’s stock valued at $6,930,000 after buying an additional 533,100 shares in the last quarter. Rock Springs Capital Management LP boosted its holdings in shares of Five Prime Therapeutics by 4.2% during the 2nd quarter. Rock Springs Capital Management LP now owns 526,100 shares of the biotechnology company’s stock valued at $3,172,000 after buying an additional 21,100 shares in the last quarter. Finally, Nuveen Asset Management LLC bought a new stake in shares of Five Prime Therapeutics during the 2nd quarter valued at $3,128,000. Hedge funds and other institutional investors own 74.23% of the company’s stock.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28.
Read More: Are all No-Load Funds Equal?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.